Sell Biocon Ltd. at a price target of Rs 208.0 and a stoploss at Rs 222 from entry point. ETMarkets.com|Updated: Aug 20, 2019, 08.53 AM ISTDr CK Narayan of Chart Advise has a sell call on Biocon Ltd. with a target price of Rs 208. The current market price of Biocon Ltd. is Rs 216.2. Time period given by the analyst is Intra Day when Biocon Ltd. price can reach the defined target. Dr CK Narayan recommended to keep stoploss at Rs 222. Biocon Ltd., incorporated in 1978, has a market cap of Rs 25944.00 crore.
Biocon Ltd. key Products/Revenue Segments include Bio Pharmaceuticals which contributed Rs 2639.20 Crore to Sales Value (91.48 % of Total Sales), Other Operating Revenue which contributed Rs 229.40 Crore to Sales Value (7.95 % of Total Sales), Waste which contributed Rs 15.10 Crore to Sales Value (0.52 % of Total Sales) and Sale of services which contributed Rs 1.00 Crore to Sales Value (0.03 % of Total Sales)for the year ending 31-Mar-2019.
For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 1465.90 Crore, down -4.11 % from last quarter Sales of Rs 1528.80 Crore and up 30.44 % from last year same quarter Sales of Rs 1123.80 Crore Company has reported net profit after tax of Rs 235.60 Crore in latest quarter. The company’s top management includes Dr.Arun Chandavarkar, Dr.Jeremy Levin, Dr.Vijay Kuchroo, Mr.Bobby Kanubhai Parikh, Mr.Daniel M Bradbury, Mr.John Shaw, Mr.Kiran Mazumdar Shaw, Mr.M Damodaran, Mr.Mary Harney, Mr.Russel Walls, Prof.Ravi Mazumdar. Company has B S R & Co. LLP as its auditors. As on 30-06-2019, the company has a total of 1,200,000,000 shares outstanding.
Read this article in :HindiAlso ReadBuy Zee Entertainment Enterprises, target Rs 358: Dr CK NarayanSell Wipro, target Rs 244: Dr CK NarayanBuy Zee Entertainment Enterprises, target Rs 351: Dr CK NarayanBuy Aurobindo Pharma, target Rs 618: Dr CK NarayanSell Mahindra & Mahindra, target Rs 500: Dr CK NarayanCommenting feature is disabled in your country/region.Disclaimer: This recommendation is analyst’s own and does not represent those of economictimes.com & ETMarkets.com. Please consult your financial advisor before taking any position in the stock/s mentioned.Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service